Clinical significance of MPL mutations in essential thrombocythemia: Analysis of the PT-1 cohort.

Clinical significance of MPL mutations in essential thrombocythemia: Analysis of the PT-1 cohort.

Dettagli Bibliografici
Autori principali:	Beer, P, Campbell, P, Erber, W, Scott, L, Bench, A, Bareford, D, Bridget, W, Wheatley, K, Buck, G, Harrison, C, Green, A
Natura:	Conference item
Pubblicazione:	2007

Documenti analoghi

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
di: Beer, P, et al.
Pubblicazione: (2008)

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
di: Campbell, P, et al.
Pubblicazione: (2009)

Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia Reply to J. Thiele et al
di: Campbell, P, et al.
Pubblicazione: (2009)

The medical research council PT1 trial in essential thrombocythemia.
di: Green, A, et al.
Pubblicazione: (2004)

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
di: Wilkins, B, et al.
Pubblicazione: (2008)

JAK2 V617F mutation identifies a biologically distinct subtype of essential thrombocythemia which resembles polycythemia vera.
di: Green, A, et al.
Pubblicazione: (2005)

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort.
di: Campbell, P, et al.
Pubblicazione: (2012)

MPL S505C enhances driver mutations at W515 in essential thrombocythemia
di: Varghese, LN, et al.
Pubblicazione: (2021)

MPL S505C enhances driver mutations at W515 in essential thrombocythemia
di: Leila N. Varghese, et al.
Pubblicazione: (2021-11-01)

MPL Y252H and MPL F126fs mutations in essential thrombocythemia: Case series and review of literature
di: Ahmed G. Elsayed, et al.
Pubblicazione: (2019-03-01)

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
di: Harrison, C, et al.
Pubblicazione: (2005)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
di: Leonardo Caires dos Santos, et al.
Pubblicazione: (2011-12-01)

MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan
di: Chiho Furuya, et al.
Pubblicazione: (2023-12-01)

Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter
di: Adrian P. Trifa, et al.
Pubblicazione: (2014-01-01)

Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations
di: Jing Wang, et al.
Pubblicazione: (2023-12-01)

Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study
di: Chao Sun, et al.
Pubblicazione: (2016-01-01)

Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia
di: Kun Liu, et al.
Pubblicazione: (2009-10-01)

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
di: Campbell, P, et al.
Pubblicazione: (2005)

Mutations and thrombosis in essential thrombocythemia
di: Paola Guglielmelli, et al.
Pubblicazione: (2021-04-01)

Prevalence of JAK2 V617F, CALR, and MPL W515L Gene Mutations in Patients with Essential Thrombocythemia in Kurdistan Region of Iraq
di: Bestoon Muhammad Saeed, et al.
Pubblicazione: (2021-03-01)

Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia
di: Ruth Morrell, et al.
Pubblicazione: (2013-01-01)

Alterations of Signaling Pathways in Essential Thrombocythemia with Calreticulin Mutation
di: Hui W, et al.
Pubblicazione: (2021-08-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
di: Mónica Mejía-Ochoa, et al.
Pubblicazione: (2019-06-01)

Classification of Philadelphia Translocation-Negative Myeloproliferative Neoplasms: Its Impact on Data From Clinical Trials Reply
di: Campbell, P, et al.
Pubblicazione: (2009)

Emerging treatments for essential thrombocythemia
di: Okoli S, et al.
Pubblicazione: (2011-12-01)

Occurrence of a paroxysmal nocturnal hemoglobinuria clone in an essential thrombocythemia: a link between <i>PIGV</i> and <i>MPL</i>
di: Alexej Knaus, et al.
Pubblicazione: (2022-01-01)

Retinal neovascularization in the setting of -mutation positive essential thrombocythemia
di: Stanton P Heydinger, et al.
Pubblicazione: (2023-08-01)

Essential Thrombocythemia
di: Kanchanee Janwanitsthaporn
Pubblicazione: (2002-08-01)

Essential thrombocythemia
di: Brière Jean B
Pubblicazione: (2007-01-01)

Ruxolitinib for the Treatment of Essential Thrombocythemia
di: Arief Gunawan, et al.
Pubblicazione: (2018-08-01)

Philadelphia-positive acute lymphoblastic leukemia in a case of MPL p.(W515L) variant essential thrombocythemia: case report and literature review
di: Jiale Ma, et al.
Pubblicazione: (2022-08-01)

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
di: Elisabeth Oppliger Leibundgut, et al.
Pubblicazione: (2020-07-01)

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia
di: Stephen E. Langabeer, et al.
Pubblicazione: (2016-01-01)

Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome
di: Bassel Nazha, et al.
Pubblicazione: (2015-01-01)

The presence of the factor V Leiden and the prothrombin G20210A polymorphism does not appear to influence the risk of thrombosis in essential thrombocythaernia: results of a nested case control study
di: Robinson, S, et al.
Pubblicazione: (2008)

Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations
di: Samah Alimam, et al.
Pubblicazione: (2018-06-01)

Neuromyotonia in association with essential thrombocythemia.
di: Benito-León, J, et al.
Pubblicazione: (2000)

Neurological disorders in essential thrombocythemia
di: Segolene Billot, et al.
Pubblicazione: (2011-12-01)

Myelofibrotic transformation in essential thrombocythemia
di: Juergen Thiele, et al.
Pubblicazione: (2009-03-01)

Thromboembolic complication in Essential Thrombocythemia
di: Zahra Mozaheb
Pubblicazione: (2012-11-01)